ExodusPoint Capital Management LP acquired a new stake in shares of Encompass Health Co. (NYSE:EHC – Free Report) in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 57,117 shares of the company’s stock, valued at approximately $3,090,000. ExodusPoint Capital Management LP owned 0.06% of Encompass Health as of its most recent SEC filing.
Several other institutional investors also recently made changes to their positions in the stock. Lazard Asset Management LLC grew its stake in shares of Encompass Health by 14.3% during the 4th quarter. Lazard Asset Management LLC now owns 1,290 shares of the company’s stock valued at $77,000 after buying an additional 161 shares during the period. Bank of Montreal Can boosted its position in Encompass Health by 1.5% during the 1st quarter. Bank of Montreal Can now owns 11,340 shares of the company’s stock worth $806,000 after purchasing an additional 173 shares during the period. Commonwealth Equity Services LLC increased its holdings in Encompass Health by 3.9% in the 4th quarter. Commonwealth Equity Services LLC now owns 4,692 shares of the company’s stock valued at $280,000 after purchasing an additional 174 shares in the last quarter. Signaturefd LLC increased its holdings in Encompass Health by 38.2% in the 1st quarter. Signaturefd LLC now owns 658 shares of the company’s stock valued at $36,000 after purchasing an additional 182 shares in the last quarter. Finally, Verdence Capital Advisors LLC increased its holdings in Encompass Health by 3.3% in the 1st quarter. Verdence Capital Advisors LLC now owns 5,698 shares of the company’s stock valued at $308,000 after purchasing an additional 183 shares in the last quarter. 92.66% of the stock is owned by hedge funds and other institutional investors.
Insider Activity
In other news, CEO Mark J. Tarr sold 25,330 shares of Encompass Health stock in a transaction that occurred on Wednesday, August 16th. The stock was sold at an average price of $71.06, for a total transaction of $1,799,949.80. Following the sale, the chief executive officer now owns 497,405 shares of the company’s stock, valued at $35,345,599.30. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In related news, insider Elissa Joy Charbonneau sold 8,294 shares of the firm’s stock in a transaction that occurred on Thursday, August 17th. The shares were sold at an average price of $69.58, for a total transaction of $577,096.52. Following the transaction, the insider now owns 23,081 shares in the company, valued at $1,605,975.98. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Mark J. Tarr sold 25,330 shares of the firm’s stock in a transaction that occurred on Wednesday, August 16th. The shares were sold at an average price of $71.06, for a total transaction of $1,799,949.80. Following the transaction, the chief executive officer now owns 497,405 shares in the company, valued at approximately $35,345,599.30. The disclosure for this sale can be found here. Corporate insiders own 1.90% of the company’s stock.
Encompass Health Stock Performance
Encompass Health (NYSE:EHC – Get Free Report) last issued its earnings results on Tuesday, August 1st. The company reported $0.95 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.74 by $0.21. Encompass Health had a net margin of 6.86% and a return on equity of 18.26%. The firm had revenue of $1.19 billion for the quarter, compared to analysts’ expectations of $1.16 billion. As a group, sell-side analysts forecast that Encompass Health Co. will post 3.45 earnings per share for the current year.
Encompass Health Announces Dividend
The firm also recently declared a quarterly dividend, which will be paid on Monday, October 16th. Stockholders of record on Monday, October 2nd will be issued a dividend of $0.15 per share. The ex-dividend date of this dividend is Friday, September 29th. This represents a $0.60 dividend on an annualized basis and a dividend yield of 0.84%. Encompass Health’s dividend payout ratio (DPR) is presently 19.29%.
Analyst Upgrades and Downgrades
Several brokerages recently issued reports on EHC. Barclays increased their price target on Encompass Health from $61.00 to $71.00 and gave the company an “equal weight” rating in a report on Thursday, August 3rd. Raymond James increased their price target on Encompass Health from $80.00 to $85.00 and gave the company a “strong-buy” rating in a report on Thursday, August 3rd. Truist Financial increased their price target on Encompass Health from $75.00 to $82.00 and gave the company a “buy” rating in a report on Thursday, August 3rd. Mizuho increased their price target on Encompass Health from $74.00 to $77.00 and gave the company a “buy” rating in a report on Thursday, August 3rd. Finally, Stephens restated an “overweight” rating and set a $78.00 target price on shares of Encompass Health in a research note on Thursday, July 20th. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $77.60.
Check Out Our Latest Analysis on Encompass Health
About Encompass Health
Encompass Health Corporation provides post-acute healthcare services in the United States. It provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.
Featured Stories
- Five stocks we like better than Encompass Health
- How to Invest in Cybersecurity
- Why Ambarella’s 20% Decline is a Strong Signal for New Investment
- Why Invest in High-Yield Dividend Stocks?
- Why Analysts Love These 2 Car Sales Platforms, And Avoid Dealers
- What Makes a Stock a Good Dividend Stock?
- A Significant Reversal is in Sight for These 5 Med Tech Companies
Want to see what other hedge funds are holding EHC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Encompass Health Co. (NYSE:EHC – Free Report).
Receive News & Ratings for Encompass Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Encompass Health and related companies with MarketBeat.com's FREE daily email newsletter.
